ALX receptor ligands define a biochemical endotype for severe asthma

Original citation: JCI Insight. 2017;2(14):1–14. https://doi.org/10.1172/jci.insight.93534

Citation for this corrigendum: JCI Insight. 2018;3(6):e120932. https://doi.org/10.1172/jci.insight.120932

Following the publication of this article, the authors became aware that there was an error in calculating the FEV1 percentage predicted, FVC percentage predicted, and FEV1/FVC percentage predicted values for subjects of mixed European descent in the SARP cohort. Correcting this error resulted in lower FEV1 and FVC percentage predicted values and slightly higher FEV1/FVC percentage predicted values — and required corrections to the spirometry data presented in Table 1, Figure 2, Figure 5F, and Supplemental Figure 2, A and B. These corrections do not change the finding that lipoxin A₄ levels positively correlate with lung function in asthma and that subjects with SAA^hiLXA₄^lo levels have lower lung function than subjects with SAA^loLXA₄^hi levels nor do they alter the conclusions of the study.

Table 1. Clinical characteristics and bronchoalveolar lavage leukocytes for subjects undergoing bronchoscopy^A.

Figure 2.

Figure 5.

The corrected versions of Figure 2, Figure 5F, and Table 1 are below. The posted supplemental data have been updated.

The authors regret the errors.

Version 1. 03/22/2018

Electronic publication